Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
Romain Marignier(Hospices Civils de Lyon), Bruce Cree(University of California, San Francisco), Ari Green(University of California, San Francisco), Jeffrey L. Bennett(University of Colorado Denver), Eliezer Katz, Fred Lublin(Icahn School of Medicine at Mount Sinai), William A. Rees(Mayo Clinic), Gary Cutter(Epilepsy Foundation), Brian G. Weinshenker(Mayo Clinic in Arizona), Orhan Aktaş(Heinrich Heine University Düsseldorf), Friedemann Paul(Max Delbrück Center), Hans‐Peter Hartung(The University of Sydney), John N. Ratchford(Johns Hopkins University), Sean J. Pittock(Mayo Clinic), Ian M. Williams(University of California, San Francisco), Ho Jin Kim(National Cancer Center), Michael Smith(Amgen (United States)), Kazuko Fujihara(University of California, San Francisco), Dewei She, Dean M. Wingerchuk(WinnMed), Daniel Cimbora, Jörn Drappa(Integrated BioTherapeutics (United States))
Cited by 42
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k